P/E ratio for Insulet (PODD)
P/E ratio as of October 2023 (TTM): 182
According to Insulet's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 182.067. At the end of 2021 the company had a P/E ratio of > 1000.
P/E ratio history for Insulet from 2007 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | > 1000 | -50.22% |
| 2020 | > 1000 | 144.34% |
| 2019 | 951 | -28.06% |
| 2018 | > 1000 | -981.33% |
| 2017 | -150 | 103.03% |
| 2016 | -73.9 | 152.07% |
| 2015 | -29.3 | -40.82% |
| 2014 | -49.5 | 10.8% |
| 2013 | -44.7 | 127.5% |
| 2012 | -19.6 | 28.34% |
| 2011 | -15.3 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 31.6 | -82.67% | 🇺🇸 USA |
 Abbott Laboratories ABT | 29.8 | -83.64% | 🇺🇸 USA |
 Medtronic MDT | 28.9 | -84.11% | 🇮🇪 Ireland |
 Eli Lilly LLY | 76.7 | -57.88% | 🇺🇸 USA |
 Tandem Diabetes Care
TNDM | -5.99 | -103.29% | 🇺🇸 USA |
 ICU Medical
ICUI | -58.7 | -132.24% | 🇺🇸 USA |
 DexCom DXCM | 103 | -43.62% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.